Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy

Circulation

Volumn 126, Issue 20, 2012, Pages 2374-2380

  Sorajja, Paul ^a   Ommen, Steve R ^a   Holmes, David R ^a   Dearani, Joseph A ^a   Rihal, Charanjit S ^a   Gersh, Bernard J ^a   Lennon, Ryan J ^a   Nishimura, Rick A ^a  

^a MAYO CLINIC   (United States)

Author keywords

ablation; alcohol; cardiomyopathy; prognosis

Indexed keywords

ALCOHOL; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE;

ADULT; AGED; ALCOHOL SEPTAL ABLATION; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; FEMALE; FOLLOW UP; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; MUSCLE RESECTION; PACEMAKER; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

ABLATION TECHNIQUES; ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84869236509     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.076257     Document Type: Article

References (31)

1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348:295-303. (Pubitemid 36119984)
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320. (Pubitemid 34250486)
3. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy. The search for obstruction. Circulation. 2006;114:2200-2202.
4. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Dan-ielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardio-myopathy. J Am Coll Cardiol. 2005;46:470-476. (Pubitemid 41040288)
5. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardio-myopathy. J Am Coll Cardiol. 2004;44:2044-2053. (Pubitemid 39480744)
6. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
7. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 55:823-834.
8. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97-104.
9. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, Spencer WH 3rd. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008;1:561-570.
10. Jensen MK, Almaas VM, Jaobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Kober L, Endresen K, Eriksson MJ, Jorgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive car-diomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4:256-265.
11. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362-369.
12. Report of the World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842.
13. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242-1244.
14. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008; 118:131-139.
15. Elesber A, Nishimura RA, Rihal CS, Ommen SR, Schaff HV, Holmes DR Jr. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy Am J Cardiol. 2008;101:516-520. (Pubitemid 351199445)
16. Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Intervent. 2005;66:375-389. (Pubitemid 41572033)
17. Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ. Utility of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006; 19:788-795. (Pubitemid 43817464)
18. WHO Monica Project Principal Investigators. The World Health Organization MONICA project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
19. Therneau T, Offord J. Expected Survival Based on Hazard Rates (update): Technical Report 63. Rochester, MN: Section of Biostatistics, Mayo Clinic;1999:1-26.
20. Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, Pellikka PA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation. 2008;117:2776-2784. (Pubitemid 351770458)
21. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:e212-e260.
22. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:350-357. (Pubitemid 46097376)
23. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardio-myopathy: a comparison of clinical, hemodynamic and exercise outcomes. Eur Heart J. 2002;23:1617-1624. (Pubitemid 35221567)
24. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JM, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myo-cardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001; 38:1994-2000. (Pubitemid 33116576)
25. Van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, Biagini E, Vletter WB, Serruys PW. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomy-opathy and enlarged anterior mitral valve leaflets. Circulation. 2005;112:482-488. (Pubitemid 41060787)
26. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG. Hypertrophic obstructive cardio-myopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129:351-358. (Pubitemid 40169559)
27. Nagueh S, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 38:1701-1706. (Pubitemid 33065457)
28. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96:864-873. (Pubitemid 350164933)
29. Chang SM, Lakkis NM, Franklin J, Spencer, WH 3rd, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:824-827. (Pubitemid 38252731)
30. Veselka J, Duchonova R, Palenickova J, Zemanek D, Svab P, Hajek P, Maly M, Blasko P, Tesar D, Cervinka P. Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Circ J. 2006;70:880-884. (Pubitemid 43979126)
31. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033-2041. (Pubitemid 40577897)